Evidence map›Paper›PMID 25302298›Full record

ReviewBioMed research international2014

Radiation oncology in vitro: trends to improve radiotherapy through molecular targets.

Natália Feofanova, Jony Marques Geraldo, Lídia Maria de Andrade

Open access · hybridAbstract readReview
In one paragraph

Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Natália FeofanovaResearch Institute of Internal and Preventive Medicine, FSBI, Boris Bogatkov Street 175/1, Novosibirsk 630089, Russia.
Jony Marques GeraldoSchool of Medicine, Federal University of Minas Gerais, Avenida Alfredo Balena, 190 Santa Efigênia, 30130-100 Belo Horizonte, MG State, Brazil ; Alberto Cavalcanti Hospital, Minas Gerais State Hospital Foundation-FHEMIG, Rua Camilo de Brito, 636 Padre Eustáquio, 30730-540 Belo Horizonte, MG, Brazil.
Lídia Maria de AndradeDepartment of Physics, Institute of Mathematical Sciences, Federal University of Minas Gerais, Avenida Antônio Carlos 6627, 31270-901 Belo Horizonte, MG, Brazil.
Universidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Much has been investigated to improve the beneficial effects of radiotherapy especially in that case where radioresistant behavior is observed. Beyond simple identification of resistant phenotype the discovery and development of specific molecular targets have demonstrated therapeutic potential in cancer treatment including radiotherapy. Alterations on transduction signaling pathway related with MAPK cascade are the main axis in cancer cellular proliferation even as cell migration and invasiveness in irradiated tumor cell lines; then, for that reason, more studies are in course focusing on, among others, DNA damage enhancement, apoptosis stimulation, and growth factors receptor blockages, showing promising in vitro results highlighting molecular targets associated with ionizing radiation as a new radiotherapy strategy to improve clinical outcome. In this review we discuss some of the main molecular targets related with tumor cell proliferation and migration as well as their potential contributions to radiation oncology improvements.

Indexed as

AnimalsForecastingHumansMolecular Targeted TherapyNeoplasm ProteinsNeoplasmsRadiation OncologyRadiotherapyNeoplasm Proteins

Identifiers

PMID25302298
PMCPMC4180203
OpenAlexW2169023273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.